

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

		ş.		
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/843,295	04/25/2001	Noel Caplice	07039-175001	7824
75	590 07/01/2002	ļ		
MARK S. ELLINGER, PH.D.		F.	EXAMINER	
Fish & Richardson P.C., P.A. Suite 3300		9 9	NAFF, DAVID M	
60 South Sixth Street Minneapolis, MN 55402			ART UNIT	PAPER NUMBER
		ŧ.	1651	
			DATE MAILED: 07/01/2002	6

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No. Applicant(s) 09/843295 Caplica atal
Office Action Summary	Examiner Group Art Unit 1651
—The MAILING DATE of this communication appears	s on the cover sheet beneath the correspondence address
Period for Reply	
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO OF THIS COMMUNICATION.	EXPIREMONTH(S) FROM THE MAILING DATE
from the mailing date of this communication.	136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS by within the statutory minimum of thirty (30) days will be considered timely. Expire SIX (6) MONTHS from the mailing date of this communication . e, cause the application to become ABANDONED (35 U.S.C. § 133).
Status	
Responsive to communication(s) filed on $\frac{4725}{6}$?/
☐ This action is FINAL.	
 Since this application is in condition for allowance except for accordance with the practice under Ex parte Quayle, 1935 	or formal matters, prosecution as to the merits is closed in C.D. 1 1; 453 O.G. 213.
Disposition of Claims	
Claim(s) [-39	is/are pending in the application.
Of the above claim(s)	is/are withdrawn from consideration.
☐ Claim(s)	is/are allowed.
□ Claim(s)	
Claim(s)	is/are objected to.
A Claim(s) 1-39	are subject to restriction or election requirement.
Application Papers	
☐ See the attached Notice of Draftsperson's Patent Drawing	Review, PTO-948.
☐ The proposed drawing correction, filed on	
☐ The drawing(s) filed on is/are objected	ed to by the Examiner.
☐ The specification is objected to by the Examiner.	
☐ The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119 (a)-(d)	
 □ Acknowledgment is made of a claim for foreign priority und □ All □ Some* □ None of the CERTIFIED copies of the 	
 □ received. □ received in Application No. (Series Code/Serial Number 	r)
received in this national stage application from the Inter	•
*Certified copies not received:	
Attachment(s)	
☐ Information Disclosure Statement(s), PTO-1449, Paper No	o(s) ☐ Interview Summary, PTO-413
□ Notice of Reference(s) Cited, PTO-892	□ Notice of Informal Patent Application, PTO-15.
Notice of Draftsperson's Patent Drawing Review, PTO-948	• •
	Action Summary

Page 2

Application Number: 09/843,295

Art Unit: 1651

5

10

Claims in the application are 1-39.

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-37, drawn to an implantable medical device that may contain cells for producing a polypeptide, classified in class 435, subclass 176.
- II. Claims 38 and 39, drawn to a method of delivering a polypeptide to a mammal by implanting the implantable medical device containing cells that produce the polypeptide, classified in class 424, subclass 93.7.

The inventions are distinct, each from the other because:

Inventions I and II are related as process and apparatus for its practice. The inventions are distinct if it can be shown that either:

(1) the process as claimed can be practiced by another materially

15 different apparatus or by hand, or (2) the apparatus as claimed can be used to practice another and materially different process. (MPEP § 806.05(e)). In this case the apparatus (implantable medical device) can be used to practice a materially different process. For example, the apparatus can be used in vitro to produce a polypeptide such an enzyme that can be used in vitro to produce a reaction product. Furthermore, the apparatus can be used in vitro to produce a cell growth polypeptide that can be used for promoting cell growth during culturing in vitro.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their

Application Number: 09/843,295

Art Unit: 1651

5

different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application.

10 Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David M. Naff whose telephone number is (703) 308-0520. The examiner can normally be reached on Monday-Thursday and every other Friday from about 8:30 AM to about 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, a message can be left on voice mail.

If attempts to reach the examiner by telephone are unsuccessful, the 20 examiner's supervisor, Mike Wityshyn, can be reached at telephone number (703) 308-4743.

The fax phone number is (703) 872-9306 before final rejection or (703) 872-9307 after final rejection.

Application Number: 09/843,295

Art Unit: 1651

Page 4

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

5

PRIMARY EXAMINER ART UNIT 1205

DMN 6/27/02